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Abstract
Background: b-Elemene, a compound found in an herb used in traditional Chinese medicine, has shown
promising anti-cancer effects against a broad spectrum of tumors. The mechanism by which b-elemene kills cells
remains unclear. The aim of the present study is to investigate the anti-tumor effect of b-elemene on human
gastric cancer cells and the molecular mechanism involved.
Results: b-Elemene inhibited the viability of human gastric cancer MGC803 and SGC7901 cells in a dose-
dependent manner. The suppression of cell viability was due to the induction of apoptosis. A robust autophagy
was observed in the cells treated with b-elemene; it was characterized by the increase of punctate LC3 dots, the
cellular morphology, and the increased levels of LC3-II protein. Further study showed that b-elemene treatment
up-regulated Atg5-Atg12 conjugated protein but had little effect on other autophagy-related proteins. PI3K/Akt/
mTOR/p70S6K1 activity was inhibited by b-elemene. Knockdown of Beclin 1 with small interfering RNA, or co-
treatment with the autophagy inhibitor, 3-methyladenine or chlorochine enhanced significantly the antitumor
effects of b-elemene.
Conclusions: Our data provides the first evidence that b-elemene induces protective autophagy and prevents
human gastric cancer cells from undergoing apoptosis. A combination of b-elemene with autophagy inhibitor
might thus be a useful therapeutic option for advanced gastric cancer.
Background
Gastric cancer is one of the top three leading causes of
cancer death in China. Most patients present with
advanced disease which limits their surgical options.
Chemotherapy is thus the major treatment for advanced
gastric cancer, but the outcome is still very poor, with a
median overall survival time of less than 1 year [1].
Combined chemotherapy with cytotoxic drugs usually
leads to severe toxicity which lowers the quality of life
of patients. Thus, new agents with high anti-tumor
activity but low side effects are urgently needed.
Elemene (1-methyl-1-vinyl-2,4-diisopropenyl-cyclohex-
ane) is a novel lipid-soluble anticancer drug extracted
from the traditional Chinese medicinal herb Rhizoma
zedoariae [2]. b-Elemene, the active component of ele-
mene, has been shown to be effective against various
tumors such as lung cancer, colorectal cancer and glio-
blastoma [3-5]. In China, b-elemene has been used to
effectively treat certain types of tumors in the clinic, and
it presents fewer side effects than other cytotoxic agents
[6,7]. However, the mechanisms by which b-elemene kills
cancer cells are still not clear. Recent studies showed that
b-elemene inhibited cell proliferation by inducing apop-
tosis as well as cell cycle arrest [3,8]. Others reported
that the apoptosis triggered by b-elemene was through
the mitochondrial-mediated pathway, as it was accompa-
nied by a reduction of Bcl-2, Bcl-X(L) and XIAP [4,9].
Yet the exact mechanisms still need to be further
elucidated.
Autophagy is an intracellular degradation system that
delivers cytoplasmic constituents to the lysosome [10].
Under normal conditions, autophagy is a mechanism for
the turnover of proteins and elimination of damaged orga-
nelles to maintain cell homeostasis [11]. It starts with the
formation of double membrane vesicles (autophagosomes)
which engulf organelles or long-lived proteins. The autop-
hagosomes then fuse with lysosomes, forming the autop-
hagolysosome, in which the contents are degraded [10,11].
It has been suggested that autophagy induced under
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response, allowing the cell to survive bioenergetic stress
[12]. However, extensive or persistent autophagy also
results in cell death [13]. Thus, autophagy is an important
and decisive factor in the balance between cell death and
survival.
Recent studies have shown that some chemotherapeu-
tics known to activate apoptosis also induce autophagy
[14]. Inhibition of autophagy by pharmacological inhibi-
tors can enhance the anti-tumor activity of cytotoxic
agents [15,16]. In these cases, autophagy serves as a pro-
tector - it prevents cells from undergoing apoptosis.
However, autophagy can also do the opposite; it can kill
cells by inducing autophagic cell death [17,18]. The
molecular mechanisms by which autophagy regulates
survival and death need to be further studied.
In the present study, we report that b-elemene induces
apoptosis as well as protective autophagy in human gastric
cancer cells. Induction of autophagy was associated with
inhibition of the PI3K/Akt/mTOR signaling pathway, and




The human gastric cancer cells MGC803 and SGC7901
were obtained from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). The
cells were cultured in RPMI-1640 medium (Gibco) con-
taining 10% heat-inactivated fetal bovine serum (FBS),
penicillin (100 U/mL) and streptomycin (100 mg/mL) at
37°C under an atmosphere of 95% air and 5% CO2. The
cells were routinely subcultured every 2-3 days, and
were all from the logarithmic phase of growth.
Reagents and antibodies
b-Elemene was obtained from Yuanda Pharmaceuticals
(Dalian, China). 3-Methyladenine (3-MA) and chloro-
chine (CQ) were purchased from Sigma-Aldrich (St.
Louis, Mo. USA). LysoTracker and Hoechst33342 were
from Invitrogen (USA). Anti-Bcl-2, anti-Bax, anti-Survi-
vin, anti-actin and anti-Akt antibodies were purchased
from Santa Cruz Biotechnology (USA). Anti-LC3, anti-
Beclin 1, anti-Atg5, anti-Atg9 and anti-Atg16L antibo-
dies were from Novus Biological (Littleton, CO, USA).
Anti-caspase 3, anti-poly(ADP-ribose) polymerase
(PARP), anti-phospho-Akt (Ser-473), anti-phospho-
mTOR, anti-mTOR, anti-phospho-p70S6K1, and anti-
p70S6K1 antibodies were purchased from Cell Signaling
Technology (USA).
Cell viability assay
Cell viability was measured using a 3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay.
The cells were seeded at 5 × 10
4 cells/well in 96-well
plates, incubated overnight and then exposed to the
indicated concentrations of b-elemene for the indicated
times. Thereafter, 20 μl of MTT solution (5 mg/mL)
was added to each well, and the cells were incubated for
another 4 h at 37°C. After removal of the culture med-
ium, the cells were lysed in 200 μl of dimethylsulfoxide
(DMSO), and the optical density (OD) was measured at
570 nm with a microplate reader (Model 550; Bio-Rad
Laboratories, USA). The following formula was used:
cell viability = (OD of the experimental sample/OD of
the control group) × 100%.
Analysis of apoptosis
Cells were seeded at 3 × 10
5 cells/well in 6-well plates,
incubated overnight and then exposed to the indicated
concentrations of b-elemene for the indicated times.
Cells were collected and incubated with 1 μg/mL
Annexin V for 20 min in the dark. Finally, the samples
were evaluated by flow cytometry and the data were
analyzed using WinMDI software.
Fluorescence microscopy
For the analysis of green fluorescent protein-fused LC3
(GFP -LC3) localization, MGC 803 cells were transfected
with a plasmid encoding GFP-LC3 (kindly provided by
Høyer-Hansen M, Danish Cancer Society) and stably
expressing cells were selected with changes of media con-
taining 200 μg/mL of G418. Transfection was performed
using Lipofectamine 2000 reagent (Invitrogen, USA),
according to the manufacturer’s instructions. After treat-
ment of 10 or 50 μg/mL b-elemene for 24 h, cells were
incubated with 50 nmol/L LysoTracker for 30 min at
room temperature, and the nucleus was stained with
Hoechst33342. The images were obtained with a fluores-
cence microscope (Olympus, Japan). The detection of
punctated GFP-LC3 co-locolized with LysoTracker indi-
cated the formation of autophagosomes.
Transmission electron microscopy
Cells were treated and collected by trypsinization, then
fixed with 2.5% phosphate-buffered gluteraldehyde, post-
fixed in 1% phosphate-buffered osmium tetroxide. Cells
were then embedded, sectioned, double stained with
uranyl acetate and lead citrate, and analyzed using a
JEM-1200EX transmission electron microscope (JEOL,
Japan).
Western blotting
Cells were washed twice with ice-cold PBS and solubilized
in 1% Triton lysis buffer [1% Triton X-100, 50 mmol/L
Tris-Cl (pH 7.4), 150 mmol/L NaCl, 10 mmol/L EDTA,
100 mmol/L NaF, 1 mmol/L Na3VO4, 1 mmol/L PMSF
and 2 μg/mL aprotinin] on ice, then quantified using the
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by sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis and electrophoretically transferred to nitrocellulose
membranes (Immoblin-P; Millipore, USA). The mem-
branes were blocked with 5% skim milk in TBST buffer
[10 mmol/L Tris (pH 7.4), 150 mmol/L NaCl and 0.1%
Tween-20] at room temperature for 1 h and incubated
overnight at 4°C with the indicated primary antibodies.
After the membranes were washed with TBST buffer, they
were reacted with the appropriate horseradish peroxidase-
conjugated secondary antibodies for 30 min at room tem-
perature. After extensive washing with TBST buffer, the
proteins were visualized with enhanced chemilumines-
cence reagent (SuperSignal Western Pico Chemilumines-
cent Substrate; Pierce, Rockford, IL, USA). The images
were analyzed using NIH Image J software.
Clonogenic assay
Cells were seeded at 5 × 10
4cells/well in 12-well plates and
treated with either 50 μg/mL b-elemene or 20 μmol/L CQ,
or co-treatment with b-elemene and CQ for 6 h. Cells
were then plated (in triplicate) at 200 cells per well into
12-well plates with fresh drug-free medium. Cells were
incubated for an additional 14 days, and the clones in each
well were stained, counted and photographed.
RNA interference
Small interfering RNA corresponding to the human Beclin
1c D N As e q u e n c e( 5 ’-CAGTTTGGCACAATCAATAtt-
3’) [19] and a control siRNA (5’-UUCUCCGAACGUGU-
CACGUtt-3’) were from Genechem Co. (Shanghai,
China). Cells were transfected with either Beclin 1 siRNA
or control siRNA at 100 nmol/L using DharmaFECT
transfection agent (Dharmacon Research, CO, USA)
according to the manufacturer’s guidelines. Forty-eight
hours after transfection, the cells were subcultured for
further use. The expression of Beclin 1 was verified by
western blotting.
Statistical analysis
The experiments were repeated at least three times.
Data are expressed as the means ± SD. Differences in
the results for two groups were evaluated by the Stu-
dent’s t-test. P < 0.05 was considered to be statistically
significant.
Results
b-Elemene inhibited cell viability and induced apoptosis
Human gastric cancer MGC803 cells were treated with
b-elemene at concentrations ranging from 10 μg/mL to
200 μg/mL for 24, 48 or 72 h. Cell viability assays showed
that b-elemene inhibited cell growth in a dose-dependent
manner (Figure 1A). The IC50 values of b-elemene at
24, 48 and 72 h were 80.03 μg/mL, 56.03 μg/mL and
45.05 μg/mL, respectively. Flow cytometry assays showed
a significant increase in the apoptotic population among
the cells treated with b-elemene at 24 h (Figure 1B). To
further confirm that apoptosis was induced by b-ele-
mene, western blotting was performed to detect the clea-
v a g eo fc a s p a s e3a sw e l la sP A R P .A ss h o w ni nF i g u r e
1C b-elemene clearly cleaved pro-caspase 3 and PARP to
their active forms. The effects of b-elemene on the
expression of apoptosis associated proteins were further
investigated. Western blotting showed that b-elemene
had little effect on the expression of Bax or Bcl-2, but sig-
nificantly down-regulated the level of Survivin (Figure 1D
and 1E). These data indicated that b-elemene inhibits cell
viability through inducing apoptosis in human gastric
cancer cells.
b-Elemene induced autophagosome formation
It has been reported that some lipid-soluble anti-tumor
agents such as oleandrin could simultaneously induce
apoptosis and autophagy [20], so we asked if there was any
autophagy in the cells treated with b-elemene. MGC803
cells stably expressing GFP-LC3 were treated with 10 or
50 μg/mL b-elemene for 24 h, and the localization of
GFP-LC3 was evaluated under fluorescent microscopy. As
shown in Figure 2A, only a few LC3-positive puncta were
observed in untreated control cells. However, in the cells
treated with 10 μg/mL b-elemene, over 30% of cells were
observed with LC3-positive puncta, and in the cells treated
with 50 μg/mL b-elemene, more than 90% of cells showed
LC3-positive puncta. GFP-LC3 co-localized with Lyso-
Tracker after treatment with b-elemene, which suggests
the accumulation of autophagosomes. The formation of
autophagosomes was further confirmed by transmission
electron microscopy. Upon treatment of 50 μg/mL b-
elemene many autophagic vesicles, double membrane
enclosed vesicle containing engulfed organelles, were
observed in the cytoplasm (Figure 2B). Meanwhile, b-
elemene treatment also significantly increased LC3-II
levels as demonstrated by western blotting (Figure 2C).
These data indicate that b-elemene treatment not only
results in apoptosis, but also induces autophagy.
Effects of b-elemene on autophagy-associated proteins
Autophagy is regulated by a group of proteins called Atg
(autophagy-related) proteins [10]. Some stimuli can mod-
ulate autophagy simply by changing the expression of
certain Atg protein [21]. To determine if b-elemene
could affect the expression of Atg proteins, MGC803
cells were treated with 50 μg/mL b-elemene for 24 h and
the levels of some Atg proteins were detected by western
blotting. After treatment with b-elemene, the level of
Atg5-Atg12 conjugated protein was up-regulated,
whereas the expression of Beclin1, Atg5, Atg9 and
Atg16L was not affected significantly (Figure 3A and 3B).
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conjugated protein might contribute to the induction of
autophagy by b-elemene.
b-elemene inhibited PI3K/Akt/mTOR signalling pathway
It has been well documented that the PI3K/Akt/mTOR/
p70S6K1 signalling pathway plays a key role in regulat-
ing both apoptosis and autophagy, so the effects of b-
elemene on the activity of this pathway were studied
next. Cells were treated with 10 or 50 μg/mL b-elemene
for 24 h, and the levels of phospho-Akt, phospho-
mTOR and phospho-p70S6K1 were detected by western
blotting. After treatment with 50 μg/mL b-elemene, the
level of phospho-Akt was obviously down-regulated,
leading to the down-regulation of downstream phospho-
mTOR as well as phospho-p70S6K1 (Figure 4A). A low
dose (10 μg/mL) of b-elemene had little effect on PI3K/
Akt/mTOR/p70S6K1 activity. Interestingly, a transient
activation of PI3K/Akt/mTOR/p70S6K1 was observed
after the cells were exposed to b-elemene for short
times. As shown in Figure 4B, the level of phospho-Akt
increased after 4 h, stayed active until 8 h, and went
down after 16 h. Similar changes were observed on the
phosphorylation of mTOR and p70S6K1. The cleavage
of PARP and conversion of LC3 I to LC3 II was also
seen following treatment with 50 μg/mL b-elemene at
16 h and 24 h, consistent with the change of PI3K/Akt/
mTOR/p70S6K1 activity (Figure 4C). These data indi-
cated that b-elemene induced apoptosis and autophagy
might be due to its inhibition of the PI3K/Akt/mTOR/
p70S6K1 signalling pathway.
b-Elemene-induced autophagy protected MGC803 cells
from undergoing apoptosis
Since autophagy can result in both survival and cell
death, we then asked whether b-elemene-induced
autophagy is protective or pro-apoptotic. MGC803
cells were treated with either 50 μg/mL b-elemene or
20 μmol/L CQ (an inhibitor of autophagy which blocks
the fusion of autophagosomes with lysosomes, stopping
autophagy at the late phase), or co-treated with b-
elemene and CQ for 24 h. Cell viability assays showed
that co-treatment with b-elemene and CQ significantly
decreased cell viability, compared with the cells treated
Figure 1 Effects of b-elemene on cell viability and apoptosis of MGC803 cells. (A) MGC803 cells were treated with b-elemene at the
indicated concentrations for 24, 48 or 72 h, and the cell viability was analyzed by MTT assay. Dots: mean of three independent experiments;
bars: SD. (B) MGC803 cells were treated with 10, 50 and 200 μg/mL b-elemene for 24 h, and apoptosis was determined by flow cytometry
followed by Annexin V staining. (C) Cells were treated with either 10 or 50 μg/mL b-elemene for 24 h, and the cleavage of caspase 3 and PARP
was detected by western blotting. (D) Cells were treated as described above, and the expression of Bcl-2, Bax and Survivin was detected by
western blotting. The results were representatives of three independent experiments. Actin was used as loading control. (E) The levels of Bcl-2,
Bax and Survivin were measured by NIH Image J software and corrected for actin. Columns: mean of three independent experiments; bars: SD. *
P<0.05 vs. untreated control.
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P<0.05) (Figure 5A). Co-treatment with b-elemene and
CQ also significantly reduced the clone formation
ability of the cells and increased the apoptotic popula-
tion compared with the cells treated with b-elemene
alone (Figure 5B and 5C). To confirm the effect of
autophagy inhibition by the pharmacologic agent CQ
on b-elemene-induced apoptosis, an RNA interference
approach was used to knock down the expression of
Beclin 1. Figure 5D shows that the level of Beclin 1
was significantly decreased in Beclin 1 siRNA-treated
cells. Compared with the results in siRNA controls,
knockdown of Beclin 1 decreased significantly the cell
viability, and enhanced b-elemene-induced apoptosis
(Figure 5 E and 5F). These data indicate that blockage
of autophagy enhanced the antitumor effect of b-
elemene in MGC803 cells.
b-Elemene induced protective autophagy in SGC7901
gastric cancer cells
To prove that the apoptosis and autophagy induced by
b-elemene is not cell-specific, we examined the antitu-
mor effect of b-elemene on another human gastric can-
cer cell line, SGC7901. We found that b-elemene
inhibited the viability of SGC7901 cells in a dose-depen-
dent manner, and the IC50 values at 24, 48 and 72 h
were 89.68 μg/mL, 75.88 μg/mL and 67.13 μg/mL,
respectively (Figure 6A). b-Elemene inhibited mTOR
activity and induced apoptosis and autophagy, which
were evidenced by the cleavage of PARP and the con-
version of LC3-I to LC3-II (Figure 6B). The contribution
of autophagy to b-elemene-induced apoptosis in
SGC7901 cells was evaluated further by co-treating the
cells with b-elemene and the autophagy inhibitor, 3-MA
or CQ. Compared with the cells treated with b-elemene
Figure 2 b-Elemene induced autophagy in MGC803 cells. (A) MGC803 cells stably expressing GFP-LC3 were treated with either 10 or 50 μg/
mL b-elemene for 24 h, stained and observed under a fluorescence microscope as described in Materials and Methods. The percentage of cells
with punctuate dots was represented with a histogram. Columns; mean of three independent experiments, bars: SD. (B) Cells were treated with
50 μg/mL b-elemene for 24 h, then harvested and subjected to transmission electron microscopy as described in Materials and Methods. (C)
After the cells were exposed to 10 or 50 μg/mL b-elemene for 24 h, cell lysates were subjected to western blotting with an anti-LC3 antibody.
The results were representatives of three independent experiments. Actin was used as loading control.
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Page 5 of 10Figure 3 Effect of b-elemene on the expression of autophagy-related proteins. (A) After the cells were exposed to 10 or 50 μg/mL b-
elemene for 24 h, cell lysates were subjected to western blotting with specific antibodies. The results were representatives of three independent
experiments. Actin was used as loading control. (B) The levels of Atg proteins were measured by NIH Image J software and corrected for actin.
Columns; mean of three independent experiments, bars: SD. * P<0.05 vs. untreated control.
Figure 4 Effect of b-elemene on the PI3K/Akt/mTOR/p70S6K1 signalling pathway. (A) MGC803 cells were exposed to 10 or 50 μg/mL b-
elemene for 24 h, and the expression of phospho-Akt, phospho-mTOR and phospho-p70S6K1 was detected by western blotting. (B) and (C)
Cells were treated with 50 μg/mL b-elemene for the indicated times, and cell lysates were subjected to western blotting with specific antibodies.
The results were representatives of three independent experiments. Actin was used as loading control.
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reduced significantly the viability and clone formation
ability of the cells, and increased the apoptotic popula-
tion (Figure 6C, D and 6E). Similar results from these
two human gastric cancer lines indicate that autophagy
induced by b-elemene served in a protective manner,
and blockage of autophagy enhanced the anti-tumor
effect of b-elemene in human gastric cancer cells.
Discussion
Recently, some traditional Chinese medicines have
exhibited promising anti-tumor activity. b-Elemene as a
novel anti-cancer herbal medicine has shown broad
anti-tumor effects in vitro and in vivo [2-5]. It has been
approved by the State Food and Drug Administration of
China for the treatment of malignant effusion and some
solid tumors. However, the effects of b-elemene on gas-
tric cancer cells have not been documented. In the pre-
sent study, we provide the first evidence that b-elemene
could inhibit the proliferation of human gastric cancer
cells.
Previous study showed that b-elemene induced both
G2/M phase arrest and apoptotic cell death in non-
small cell lung cancer cells [3]; whereas in ovarian carci-
noma cells it only induced cell cycle arrest at G2/M
phase [8]. In the present study b-elemene induced
obvious apoptosis in gastric cancer cells, but had little
effect on cell cycle distribution. This may be due to the
Figure 5 Inhibition of autophagy enhanced the anti-tumor effect of b-elemene on MGC803 cells. (A) MGC803 cells were exposed to
either 50 μg/mL b-elemene or 20 μmol/L CQ, or a combined treatment of b-elemene and CQ for 24 h, and cell viability was measured by MTT
assay. (B) Cells were treated with 50 μg/mL b-elemene or 20 μmol/L CQ, or a combined treatment of b-elemene and CQ for 6 h, and the clone
formation ability was analyzed. Columns: mean of three independent experiments; bars: SD. * P<0.05 vs. cells treated with b-elemene alone. (C)
Cells were treated as described in A and apoptosis was analyzed by flow cytometry following Annexin V staning. (D) Cells were transfected with
either Beclin1 siRNA or a non-target control siRNA for 48 h, and the expression of Beclin 1 was verified by western blotting. (E) and (F) Forty-
eight hours after transfection, the cells were treated with 50 μg/mL b-elemene for another 24 h, and cell viability (E) and apoptosis (F) were
analyzed. * P<0.05 vs. cells transfected with control siRNA.
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different types of tumor cells.
Meanwhile, in our study a robust autophagy was
observed among the cells treated with b-elemene, which
was shown by the increase of punctate LC3 and the
morphologic changes. Western blotting also showed a
conversion of LC3-I to LC3-II. These specific changes of
LC3 have been characterized as an autophagosomal
marker in mammalian autophagy. This is the first
demonstration that b-elemene could induce autophagy.
It has been demonstrated that autophagy is activated by
some anti-tumor drugs while they induce apoptosis
[14-16]. The autophagy induced by these agents leads to
either survival or autophagic cell death. Whether b-ele-
mene-induced autophagy is a protective or a deadly
response was confirmed later.
Although the detailed mechanisms regulating autop-
hagy have not been well documented, just like for apop-
tosis, the process of autophagy is controlled under a
group of evolutionarily conserved proteins, the Atg pro-
teins [10]. Accumulated evidence suggest that the induc-
tion of autophagy is associated with the up-regulation of
certain Atg proteins [21-23]. Thyagarajan et al. reported
that triterpenes-induced autophagy is accompanied by
the up-regulation of Beclin 1 [21]. Others reported that
increased transcription of Atg5 can lead to autophagy
[23]. In the present study b-elemene induced autophagy
without alternating significantly the levels of Beclin 1,
Atg5, Atg9 or Atg16L, while the expression of the Atg5-
Atg12 conjugated protein was up-regulated significantly.
This is similar to the results reported by Kim et al that
irradiation up-regulated Atg5-Atg12 and activated
Figure 6 Anti-tumor effect of b-elemene on SGC7901 gastric cancer cells. (A) SGC7901 cells were treated with b-elemene at the indicated
concentrations for 24, 48 or 72 h, and the cell viability was analyzed by the MTT assay. Dots: mean of three independent experiments; bars: SD.
(B) Cells were treated with 20 or 100 μg/mL b-elemene for 24 h, and cell lysates were subjected to western blotting with specific antibodies. (C)
Cells were exposed to either 100 μg/mL b-elemene, 10 mmol/L 3-MA, 20 μmol/L CQ, or a combined treatment of b-elemene and 3-MA or CQ
for 24 h, and cell viability was measured by the MTT assay. (D) Cells were treated with 100 μg/mL b-elemene, 10 mmol/L 3-MA, 20 μmol/L CQ,
or a combined treatment of b-elemene and 3-MA or CQ for 6 h, and the clone formation ability was analyzed. Columns: mean of three
independent experiments; bars: SD. * P<0.05 vs. cells treated with b-elemene alone. (E) Cells were treated as described in A and apoptosis was
analyzed by flow cytometry following Annexin V staning.
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changes of these molecular markers finally lead to
autophagy.
The PI3K/Akt pathway has been reported to play an
important role in the inhibition of apoptosis [25-28].
Once activated, Akt phosphorylates downstream mTOR,
leading to the phospharylation of its target p70S6K1,
which promotes cell growth and inhibits apoptosis [29].
Moreover, recent studies have suggested that Survivin is
positively regulated by the PI3K/Akt/p70S6K1 pathway
[30]. In our study b-elemene inhibited the phospharyla-
tion of Akt, mTOR, and p70S6K1, and down-regulated
the expression of Survivin but not other apoptotic pro-
teins. This indicated that inhibition of PI3K/Akt/mTOR/
p70S6K1 and Survivin by b-elemene might lead to the
induction of apoptosis. Meanwhile, mTOR is also a key
regulator of autophagy, and inhibition of mTOR activity
by some agents has been reported to activate autophagy
[31-33]. This may explain the phenomenon of autop-
hagy among the cells treated with b-elemene in the pre-
sent study.
Since autophagy can result in both survival and cell
death, we then investigated whether the autophagy
induced by b-elemene was a protective response or a
process leading to death. We found that inhibition of
autophagy by the autophagy inhibitor, or by genetic
knockdown of Beclin 1, the Atg protein essential for
autophagy initiation, enhanced significantly the antitu-
mor effect of b-elemene. This phenomenon was also
seen in another gastric cancer cell line, SGC7901. These
data suggest that the inhibition of PI3K/Akt/mTOR
activity by b-elemene resulted in two opposite conse-
quences: on the one hand, it inhibited cell viability and
induced apoptosis, which led to death; on the other
hand, it activated a protective autophagy to adapt to the
stressful conditions and protect cells from death. Inhibi-
tion of protective autophagy might be a good way to
enhance the anti-tumor effect of b-elemene.
Conclusions
Taken together, our study provides the first evidence
that b-elemene can inhibit the proliferation of human
gastric cancer cells by inducing apoptosis. The anti-can-
cer effect of b-elemene was associated with inhibition of
the PI3K/Akt/mTOR/p70S6K1 signaling pathway, which
also led to the activation of a protective autophagy. Inhi-
bition of autophagy significantly enhanced the apopto-
sis-inducing ability, which suggests that the combination
of b-elemene with an autophagy inhibitor might be use-
ful for the treatment of advanced gastric cancer.
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